WO2022228555A1 - 一种聚合物及其组合物 - Google Patents
一种聚合物及其组合物 Download PDFInfo
- Publication number
- WO2022228555A1 WO2022228555A1 PCT/CN2022/090327 CN2022090327W WO2022228555A1 WO 2022228555 A1 WO2022228555 A1 WO 2022228555A1 CN 2022090327 W CN2022090327 W CN 2022090327W WO 2022228555 A1 WO2022228555 A1 WO 2022228555A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- integer
- temperature
- polymer
- poly
- composition
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 178
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 125000003118 aryl group Chemical group 0.000 claims abstract description 51
- 239000003814 drug Substances 0.000 claims abstract description 44
- 229940079593 drug Drugs 0.000 claims abstract description 42
- 229920001577 copolymer Polymers 0.000 claims abstract description 32
- 239000012867 bioactive agent Substances 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims description 66
- 239000000499 gel Substances 0.000 claims description 65
- -1 cyano, amino Chemical group 0.000 claims description 64
- 239000000017 hydrogel Substances 0.000 claims description 43
- 125000000217 alkyl group Chemical group 0.000 claims description 42
- 125000003545 alkoxy group Chemical group 0.000 claims description 38
- 125000001072 heteroaryl group Chemical group 0.000 claims description 37
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 34
- 230000002209 hydrophobic effect Effects 0.000 claims description 33
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 32
- 230000007704 transition Effects 0.000 claims description 32
- 229910052805 deuterium Inorganic materials 0.000 claims description 31
- 229910052736 halogen Inorganic materials 0.000 claims description 31
- 150000002367 halogens Chemical group 0.000 claims description 31
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 229920001223 polyethylene glycol Polymers 0.000 claims description 27
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 25
- 239000013543 active substance Substances 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 239000002202 Polyethylene glycol Substances 0.000 claims description 20
- 125000004043 oxo group Chemical group O=* 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical group CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 14
- VSKXVGWORBZZDY-UHFFFAOYSA-N 2-hydroxypropanoic acid;oxepan-2-one Chemical compound CC(O)C(O)=O.O=C1CCCCCO1 VSKXVGWORBZZDY-UHFFFAOYSA-N 0.000 claims description 13
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 125000004450 alkenylene group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000004419 alkynylene group Chemical group 0.000 claims description 9
- 125000002993 cycloalkylene group Chemical group 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 125000005549 heteroarylene group Chemical group 0.000 claims description 8
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 8
- 125000000732 arylene group Chemical group 0.000 claims description 7
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 6
- 229960000448 lactic acid Drugs 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 239000004632 polycaprolactone Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 claims description 5
- 108010039918 Polylysine Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 229940022769 d- lactic acid Drugs 0.000 claims description 5
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims description 5
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 5
- 108010054442 polyalanine Proteins 0.000 claims description 5
- 108010011110 polyarginine Proteins 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 5
- 108010094020 polyglycine Proteins 0.000 claims description 5
- 229920000232 polyglycine polymer Polymers 0.000 claims description 5
- 229920000656 polylysine Polymers 0.000 claims description 5
- 108010055896 polyornithine Proteins 0.000 claims description 5
- 229920002714 polyornithine Polymers 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 5
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 4
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229920002643 polyglutamic acid Polymers 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 3
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 claims description 3
- 150000008065 acid anhydrides Chemical class 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000002971 oxazolyl group Chemical group 0.000 claims description 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 3
- 230000002459 sustained effect Effects 0.000 claims description 3
- 125000000335 thiazolyl group Chemical group 0.000 claims description 3
- 125000001425 triazolyl group Chemical group 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 239000008366 buffered solution Substances 0.000 claims description 2
- 238000012412 chemical coupling Methods 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical group C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- HRMMNIKBLMRRJP-UHFFFAOYSA-N 2,4-dimethylpentane Chemical compound CC(C)[C]C(C)C HRMMNIKBLMRRJP-UHFFFAOYSA-N 0.000 claims 1
- XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical group C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims 1
- 229910000071 diazene Inorganic materials 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 229920000118 poly(D-lactic acid) Polymers 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 30
- 238000002360 preparation method Methods 0.000 abstract description 6
- 239000000243 solution Substances 0.000 description 42
- 125000004432 carbon atom Chemical group C* 0.000 description 23
- 238000005227 gel permeation chromatography Methods 0.000 description 22
- 239000012071 phase Substances 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 20
- 229920000747 poly(lactic acid) Polymers 0.000 description 20
- 229920000382 poly(ethylene glycol) methyl ether-block-poly(L-lactide-co-glycolide) Polymers 0.000 description 16
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 12
- 125000000000 cycloalkoxy group Chemical group 0.000 description 12
- 125000004465 cycloalkenyloxy group Chemical group 0.000 description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 10
- 229960002390 flurbiprofen Drugs 0.000 description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 10
- 229920001427 mPEG Polymers 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000005133 alkynyloxy group Chemical group 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 8
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 7
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000001291 vacuum drying Methods 0.000 description 7
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 239000010432 diamond Substances 0.000 description 6
- 239000012467 final product Substances 0.000 description 6
- 238000010587 phase diagram Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000008096 xylene Substances 0.000 description 5
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 108010039177 polyphenylalanine Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229910003460 diamond Inorganic materials 0.000 description 3
- 229920000359 diblock copolymer Polymers 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 125000003003 spiro group Chemical group 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 3
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- VLDPXPPHXDGHEW-UHFFFAOYSA-N 1-chloro-2-dichlorophosphoryloxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(Cl)=O VLDPXPPHXDGHEW-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001335 aliphatic alkanes Chemical group 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229920000469 amphiphilic block copolymer Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical class [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012069 chiral reagent Substances 0.000 description 2
- 125000005366 cycloalkylthio group Chemical group 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- ANSXAPJVJOKRDJ-UHFFFAOYSA-N furo[3,4-f][2]benzofuran-1,3,5,7-tetrone Chemical compound C1=C2C(=O)OC(=O)C2=CC2=C1C(=O)OC2=O ANSXAPJVJOKRDJ-UHFFFAOYSA-N 0.000 description 2
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 2
- 229920000578 graft copolymer Polymers 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920001420 poly(caprolactone-co-lactic acid) Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004336 3,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000012604 3D cell culture Methods 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000662429 Fenerbahce Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920000436 Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide) Polymers 0.000 description 1
- 229910020008 S(O) Chemical group 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical class [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003302 alkenyloxy group Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002579 anti-swelling effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004976 cyclobutylene group Chemical group 0.000 description 1
- 125000004977 cycloheptylene group Chemical group 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000004978 cyclooctylene group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004979 cyclopentylene group Chemical group 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 150000001975 deuterium Chemical group 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-BJUDXGSMSA-N iodoethane Chemical class [11CH3]CI HVTICUPFWKNHNG-BJUDXGSMSA-N 0.000 description 1
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical class I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920005684 linear copolymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000006578 monocyclic heterocycloalkyl group Chemical group 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000008385 outer phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 125000005570 polycyclic cycloalkylene group Chemical group 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
Definitions
- the present disclosure belongs to the field of medicine, and relates to a temperature-sensitive polymer, a preparation method thereof and its application in medicine.
- the present disclosure relates to a thermosensitive star polymer for use in the preparation of a hydrogel long-acting sustained-release formulation.
- Hydrogel is a polymer network system with a hydrophilic three-dimensional network structure, which is soft in shape and maintains a specific shape, and has good biocompatibility. It has been widely used in various aspects, such as tissue engineering, Drug delivery, 3D cell culture and other medical fields.
- thermosensitive hydrogel material that is in a gel state near the human body temperature and is in a solution state when it deviates from the human body temperature, which is particularly important in biomedicine.
- This thermosensitive hydrogel can embed biologically active substances such as polypeptides, proteins, cells, etc. in solution state.
- the solution embedded with active substances When injected into subcutaneous tissue and muscle tissue, the solution embedded with active substances rapidly turns into a gel due to temperature changes. , the active substance is steadily released from the inside of the gel under the dual promotion of diffusion and the degradation of the gel itself, achieving the effect of long-term sustained release.
- the injection implantation of thermosensitive hydrogel is simpler and easier to use than the implantation of other solid preparations, without surgery, and with less trauma.
- Amphiphilic block copolymers include linear copolymers, star copolymers, graft copolymers and dendritic copolymers, while the research on amphiphilic block copolymers for hydrogel preparation mostly focuses on linear block copolymers. copolymer.
- MacroMed has developed a linear injectable thermosensitive hydrogel PLGA-PEG-PLGA (1500-1000-1500) with the trade name ReGel for drug carrier.
- the triblock copolymer mPEG-PLGA-mPEG was first reported by Jeong et al. The aqueous polymer solution was free-flowing at room temperature and formed a gel when raised to body temperature. The solution formed a gel in situ after injection into the back of mice (see "Biodegradable block copolymers as injectable drug-delivery systems.” Nature. 1997 Aug 28; 388(6645): 860-2. doi: 10.1038/42218).
- thermosensitive polymer or compound having a star-shaped multi-arm structure including an aromatic core and a biodegradable AB-type amphiphilic copolymer
- the biodegradable AB-type amphiphilic copolymer Contains a hydrophobic A block and a hydrophilic B block.
- the hydrophilic B block comprises from about 10 to about 90 wt% of the biodegradable AB-type amphiphilic copolymer. In some embodiments, the hydrophilic B block comprises about 20 to about 80 wt %, about 20 to about 60 wt %, about 25 to about 50 wt %, or about 30 wt % of the biodegradable AB-type amphiphilic copolymer About 40 wt%.
- the hydrophilic B block comprises about 10 wt%, 11 wt%, 12 wt%, 13 wt%, 14 wt%, 15 wt%, 16 wt% of the biodegradable AB-type amphiphilic copolymer , 17wt%, 18wt%, 19wt%, 20wt%, 21wt%, 22wt%, 23wt%, 24wt%, 25wt%, 26wt%, 27wt%, 28wt%, 29wt%, 30wt%, 31wt%, 32wt%, 33wt% %, 34wt%, 35wt%, 36wt%, 37wt%, 38wt%, 39wt%, 40wt%, 41wt%, 42wt%, 43wt%, 44wt%, 45wt%, 46wt%, 47wt%, 48wt%, 49wt%, 50wt%, 51wt%, 52wt
- the hydrophobic A block comprises from about 90 to about 10 wt% of the biodegradable AB-type amphiphilic copolymer. In some embodiments, the hydrophobic A block comprises about 80 to about 20 wt%, about 80 to about 40 wt%, about 75 to about 50 wt%, about 70 to about 70 wt% of the biodegradable AB-type amphiphilic copolymer 60wt%.
- the hydrophobic A blocks comprise about 90, 89, 88, 87, 86, 85, 84, 83 wt% of the biodegradable AB-type amphiphilic copolymer , 82wt%, 81wt%, 80wt%, 79wt%, 78wt%, 77wt%, 76wt%, 75wt%, 74wt%, 73wt%, 72wt%, 71wt%, 70wt%, 69wt%, 68wt%, 67wt%, 66wt% %, 65wt%, 64wt%, 63wt%, 62wt%, 61wt%, 60wt%, 59wt%, 58wt%, 57wt%, 56wt%, 55wt%, 54wt%, 53wt%, 52wt%, 51wt%, 50wt%, 49wt%, 48wt%, 47
- the solution of the thermosensitive polymer or compound undergoes a solution-gel phase transition with increasing temperature, and the temperature of the solution-gel phase transition is from about 4°C to about 40°C; in some embodiments, the solution - The temperature of the gel phase transition is from about 10°C to about 37°C, from about 20°C to about 37°C.
- the temperature of the solution-gel phase transition is about 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C, 14°C, 15°C °C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C or 40°C.
- the hydrophilic B block is selected from polyethylene glycol, or polyvinylpyrrolidone. In some embodiments, is selected from polyethylene glycols. In some embodiments, polyethylene glycol in the form of monomethyl ether, monoethyl ether is selected.
- the hydrophilic B block has a weight average molecular weight of from about 100 to about 20,000. In some embodiments, the hydrophilic B block has a weight average molecular weight of from about 200 to about 5300. In some embodiments, the hydrophilic B block has a weight average molecular weight of from about 400 to about 1000.
- the hydrophilic B block has a weight average molecular weight of about 200, 300, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550 ,560,570,580,590,600,700,800,900,1000,2000,3000,4000,5000,6000,7000,8000,9000,10000,11000,12000,13000,14000,15000,16000,17000 , 18000, 19000 or 20000.
- the hydrophilic B block number average molecular weight is less than the weight average molecular weight.
- the hydrophilic B block has a number average molecular weight of from about 100 to about 20,000. In some embodiments, the hydrophilic B block has a number average molecular weight of from about 200 to about 5300. In some embodiments, the hydrophilic B block has a number average molecular weight of from about 400 to about 1000.
- the hydrophilic B block has a number average molecular weight of about 200, 300, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 16000, 17000, 18000, 19000 or 20000.
- the number average molecular weight (Mn) and weight average molecular weight (Mw) of the hydrophilic B block are measured by gel permeation chromatography (GPC, polyethylene glycol as a standard).
- the hydrophobic A block is selected from polyesters or polyamino acids.
- the hydrophobic A block has a weight average molecular weight of from about 72 to about 60,000. In some embodiments, the hydrophobic A block has a weight average molecular weight of from about 150 to about 20,000. In some embodiments, the hydrophobic A block has a weight average molecular weight of from about 200 to about 15,000. In some embodiments, the hydrophobic A block has a weight average molecular weight of from about 300 to about 10,000. In some embodiments, the hydrophobic A block has a weight average molecular weight of from about 400 to about 8000. In some embodiments, the hydrophobic A block has a weight average molecular weight of from about 500 to about 3000. In some embodiments, the hydrophobic A block has a weight average molecular weight of from about 700 to about 2000.
- the hydrophobic A block has a weight average molecular weight of about 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000 or 60000.
- the hydrophobic A block number average molecular weight is less than the weight average molecular weight.
- the hydrophobic A block has a number average molecular weight of from about 72 to about 60,000. In some embodiments, the hydrophobic A block has a number average molecular weight of from about 150 to about 20,000. In some embodiments, the hydrophobic A block has a number average molecular weight of from about 200 to about 15,000. In some embodiments, the hydrophobic A block has a number average molecular weight of from about 300 to about 10,000. In some embodiments, the hydrophobic A block has a number average molecular weight of from about 400 to about 8000. In some embodiments, the hydrophobic A block has a number average molecular weight of from about 500 to about 3000. In some embodiments, the hydrophobic A block has a number average molecular weight of from about 700 to about 2000.
- the hydrophobic A block has a number average molecular weight of about 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89 , 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500 , 1600, 1700, 1800, 1900, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 30000, 40000, 50000, or 60000.
- the number-average molecular weight (Mn) and weight-average molecular weight (Mw) of the hydrophobic A block are measured by gel permeation chromatography (GPC, polyethylene glycol as a standard).
- the temperature-sensitive polymers or compounds of the present disclosure have a weight average molecular weight of from about 200 to about 300,000. In some embodiments, the temperature-sensitive polymer or compound has a weight average molecular weight of from about 500 to about 100,000. In some embodiments, the temperature-sensitive polymer or compound has a weight average molecular weight of from about 1,000 to about 50,000. In some embodiments, the temperature-sensitive polymer or compound has a weight average molecular weight of from about 2,000 to about 10,000. In some embodiments, the temperature sensitive polymer or compound has a weight average molecular weight of from about 1000 to about 8000.
- the temperature-sensitive polymers or compounds of the present disclosure have a weight average molecular weight of about 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 ,1800,1900,2000,2100,2200,2300,2400,2500,2600,2700,2800,2900,3000,3100,3200,3300,3400,3500,3600,3700,3800,3900,4000,4100,4200 ,4300,4400,4500,4600,4700,4800,4900,5000,5100,5200,5300,5400,5500,5600,5700,5800,5900,6000,6100,6200,6300,6400,6500,6600,6700 ,6800,6900,7000,7100,7200,7300,7400,7500,7600,7700,7800,7900,8000,8100
- the temperature-sensitive polymer or compound of the present disclosure has a number average molecular weight less than a weight average molecular weight.
- the temperature-sensitive polymers or compounds of the present disclosure have a number average molecular weight of from about 200 to about 300,000. In some embodiments, the temperature-sensitive polymer or compound has a number average molecular weight of from about 500 to about 100,000. In some embodiments, the temperature-sensitive polymer or compound has a number average molecular weight of from about 1,000 to about 50,000. In some embodiments, the temperature-sensitive polymer or compound has a number average molecular weight of from about 2,000 to about 10,000. In some embodiments, the temperature sensitive polymer or compound has a number average molecular weight of from about 800 to about 7000.
- the temperature-sensitive polymers or compounds of the present disclosure have a number average molecular weight of about 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 ,1800,1900,2000,2100,2200,2300,2400,2500,2600,2700,2800,2900,3000,3100,3200,3300,3400,3500,3600,3700,3800,3900,4000,4100,4200 ,4300,4400,4500,4600,4700,4800,4900,5000,5100,5200,5300,5400,5500,5600,5700,5800,5900,6000,6100,6200,6300,6400,6500,6600,6700 ,6800,6900,7000,7100,7200,7300,7400,7500,7600,7700,7800,7900,8000,8100
- the number-average molecular weight (Mn) and weight-average molecular weight (Mw) of the temperature-sensitive polymer or compound are measured by gel permeation chromatography (GPC, polyethylene glycol as a standard).
- the temperature-sensitive polymer or compound of the present disclosure has a molecular weight distribution coefficient (Mw/Mn) of less than 2.
- the temperature-sensitive polymers or compounds of the present disclosure have a molecular weight distribution coefficient (Mw/Mn) of less than 2. In some embodiments, the molecular weight distribution coefficient is less than 1.5. In some embodiments, the molecular weight distribution coefficient is less than 1.4. In some embodiments, the molecular weight distribution coefficient is less than 1.3. In some embodiments, the molecular weight distribution coefficient is less than 1.2. In some embodiments, the molecular weight distribution coefficient is less than 1.18. In some embodiments, the molecular weight distribution coefficient is less than 1.15.
- Mw/Mn molecular weight distribution coefficient
- the molecular weight distribution coefficient of the temperature-sensitive polymer or compound of the present disclosure is selected from the group consisting of about 1.15, 1.16, 1.17, 1.18, 1.19, 1.20, 1.21, 1.22, 1.23, 1.24, 1.25, 1.26, 1.27, 1.28, 1.29, 1.30, 1.31, 1.32, 1.33, 1.34, 1.35, 1.36, 1.37, 1.38, 1.39, 1.40, 1.41, 1.42, 1.43, 1.44, 1.45, 1.46, 1.47, 1.48, 1.49, 1.50, 1.51, 1.52, 1.53, 1.54, 1.55, 1.56, 1.57, 1.58, 1.59, 1.60, 1.61, 1.62, 1.63, 1.64, 1.65, 1.66, 1.67, 1.68, 1.69, 1.70, 1.71, 1.72, 1.73, 1.74, 1.75, 1.76, 1.77, 1.78, 1.79, 1.80, 1.81, 1.82, 1.83, 1.84, 1.85, 1.86, 1.87, 1.88, 1.89, 1.90
- thermosensitive polymer or compound has the structure of formula (I),
- R 1 are the same or different, and are each independently selected from C 1 -C 12 alkyl (eg C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 , C 10 ) , C 11 , C 12 ), the C 1 -C 12 alkyl is optionally substituted with one or more substituents selected from halogen, hydroxy, alkoxy, haloalkoxy, cyano, amino and nitro;
- R 2 and R 3 are the same or different, each independently selected from absence, -O-, -S-, -SO-, -SO 2 -, -C(O)-, -C(O)O-, - NR'-, -C(O)NR'-, alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, PEG, carbon number 1-20 (eg 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) Alkyl groups that may have a branched structure, or carbon number 1-20 (eg 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20) can have a branched alkoxy group; the alkylene group, alkenylene group, alkynylene group, heteroalkylene group, cycloalkylene group, heterocycloalkylene group, arylene group, heteroarylene, alkyl
- Ring E is the same or different, and each is independently selected from aryl or heteroaryl; in some embodiments, Ring E is the same or different, and each is independently selected from C 6 -C 12 (eg, C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12 ) aryl or 5-10 membered (eg, 5-, 6-, 7-, 8-, 9-, 10-membered) heteroaryl; in some embodiments, Ring E The same or different, each independently selected from phenyl, pyridyl, pyrazinyl, pyrazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, imidazolyl, indazolyl or benzimidazolyl or;
- C 6 -C 12 eg, C 6 , C 7 , C 8 , C 9 , C 10 , C 11 , C 12
- Ring E The same or different
- L is the same or different, and each is independently selected from a bond, -C(O)-, -O-, -S-, -SO-, -SO2- , -C(O)O-, -NR'-, -C(O)NR'-, alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene, PEG, said Alkylene, alkenylene, alkynylene, heteroalkylene, cycloalkylene, heterocycloalkylene, arylene, heteroarylene are optionally selected from hydroxy, alkyl, alkoxy, One or more substituents of haloalkyl, haloalkoxy, halogen, cyano, amino and nitro are substituted; the R' is selected from hydrogen, deuterium, hydroxyl, alkyl, alkoxy, cycloalkyl, heterocycle aryl, aryl or heteroary
- A is selected from hydrophobic blocks
- the hydrophobic block is selected from polyesters or polyamino acids; in some embodiments, the hydrophobic block is selected from poly-DL-lactic acid, poly-D-lactic acid, poly-L-lactic acid, poly(DL-lactic acid-ethanol) acid), poly(L-lactic-glycolic acid), poly(D-lactic-glycolic acid), poly-caprolactone, poly(DL-lactic-caprolactone), poly(L-lactic-caprolactone), poly- One of (D lactic acid-caprolactone), polyglycine, polyalanine, polyphenylalanine, polyglutamic acid, polylysine, polyornithine, polyarginine or its copolymer;
- B is selected from hydrophilic blocks
- the hydrophilic block is selected from polyethylene glycol, or polyvinylpyrrolidone; in some embodiments, the hydrophilic block is selected from polyethylene glycol; in some embodiments, the hydrophilic block is selected from Polyethylene glycol in the form of monomethyl ether, monoethyl ether, dimethyl ether or glycerol ether;
- W is the same or different, and each is independently selected from a bond, -O-, -S-, -SO-, -SO 2 -, -C(O)-, -C(O)O-, -NR'-, -C(O)NR'-, alkylene, said alkylene optionally being selected from one of hydroxy, alkyl, alkoxy, haloalkyl, haloalkoxy, halo, cyano, amino and nitro or more substituents;
- the R' is selected from hydrogen, deuterium, hydroxyl, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl optionally substituted with one or more substituents selected from halogen, hydroxy, oxo, nitro, cyano;
- n is selected from an integer between 1-300; in some embodiments, m is selected from an integer between 5-150; in some embodiments, m is selected from an integer between 10-120; in some embodiments, m is selected from an integer from 10-45; in some embodiments, m is selected from an integer between 15-25;
- m is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,
- n is selected from an integer between 1-500; in some embodiments, n is selected from an integer between 5-300; in some embodiments, n is selected from an integer between 10-45; in some embodiments, n is selected from an integer from 10-30; in some embodiments, n is selected from an integer between 10-20;
- n is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,
- a is selected from an integer between 1-20; in some embodiments, selected from an integer between 2-15; in some embodiments, selected from an integer between 3-11; in some embodiments, selected from 4- an integer between 8;
- a is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20;
- b is selected from 1, 2, 3, 4, 5, 6;
- the structure of formula (I) is selected from:
- R 1 , R 2 , R 3 , rings E, L, A, B, W, m, n, a, b are as defined in formula (I).
- formula (I-1) is selected from
- c is selected from an integer between 1-8, such as 1, 2, 3, 4, 5, 6, 7, 8;
- d is the same or different, each independently selected from an integer between 1-8; for example, 1, 2, 3, 4, 5, 6, 7, 8;
- R 1 , rings E, L, A, B, W, m, n, a, b are as defined in formula (I).
- formula (I-3) is selected from:
- c is selected from the integer between 1-8, such as 1, 2, 3, 4, 5, 6, 7, 8;
- d is the same or different, each independently selected from an integer between 1-8, such as 1, 2, 3, 4, 5, 6, 7, 8;
- R 1 , R 3 , rings E, L, A, B, W, m, n, a, b are as defined in formula (I).
- Ring E is selected from phenyl.
- formula (I) is selected from:
- c is selected from an integer between 1-8, such as 1, 2, 3, 4, 5, 6, 7, 8;
- d is the same or different, each independently selected from an integer between 1-8, such as 1, 2, 3, 4, 5, 6, 7, 8;
- R 1 , R 2 , R 3 , L, A, B, W, m, n, a are as defined in formula (I).
- L is the same or different, each independently selected from bond, -C(O)-, -O-, - S-, -SO-, -SO 2 -, -C(O)O-, -NR'-, -C(O)NR'-, C 1 -C 6 alkylene (eg C 1 , C 2 , C3, C4 , C5 , C6 ) , PEG, the alkylene group is optionally selected from hydroxy, alkyl, alkoxy, haloalkyl, haloalkoxy, halo, cyano, amino and nitro substituted with one or more substituents; the R' is selected from hydrogen, deuterium, hydroxyl, C 1 -C 6 alkyl (eg C 1 , C 2 , C 3 , C 4 , C 5 , C 6 ), C 1 - C6 alkoxy (eg C 1 , C 1 , C 1 , C 1 , C 2 , C 3 , C 4
- W is the same or different, and each is independently selected from bond, -O-, -C(O)-, -NH-.
- R 1 is the same or different, and each is independently selected from C 1 -C 6 alkyl (such as C 1 , C 2 , C 3 , C 4 , C 5 , C 6 ), the C 1 -C 6 alkyl is optionally selected from halogen, hydroxy, alkoxy, haloalkoxy, cyano, amino and nitro Substituted by one or more substituents; preferably selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, optionally by one or more selected from hydroxy, alkyl, Substituent substitution of alkoxy, haloalkyl, haloalkoxy, halogen, hydroxy, cyano, amino and nitro.
- R 3 is selected from bond, -O-, -S-, -SO-, -SO 2 -, - C(O)-, -C(O)O-, -NR'-, -C(O)NR'-, C 1 -C 6 alkylene (eg C 1 , C 2 , C 3 , C 4 , C 5 , C 6 ), PEG, the C 1 -C 6 alkylene optionally selected from the group consisting of hydroxy, alkyl, alkoxy, haloalkyl, haloalkoxy, halo, cyano, amino and nitro One or more substituents are substituted; the R' is selected from hydrogen, deuterium, hydroxyl, C1 - C6 alkyl (eg C1 , C2 , C3, C4 , C5 , C6 ), C1 -C 6 alkoxy (eg C 1 ,
- a is the same or different, and each is independently selected from 1, 2, 3, 4, 5, and 6.
- n -R 1 is selected from -(CH 2 CH 2 O)nR 1 , wherein, R 1 is as defined above, n is selected from an integer between 1-500; in some embodiments, n is selected from an integer between 10-300; in some embodiments, n is selected from an integer between 5-150; In some embodiments, n is selected from an integer between 10-120; in some embodiments, n is selected from an integer between 10-45; in some embodiments, n is selected from an integer between 10-20.
- n is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,
- -(A) m- is selected from polyester or polyamino acid; in some embodiments, the -(A) ) m - selected from poly-DL-lactic acid, poly-D-lactic acid, poly-L-lactic acid, poly(DL-lactic-glycolic acid), poly(L-lactic-glycolic acid), poly(D-lactic-glycolic acid), Poly-caprolactone, poly(DL lactic acid-caprolactone), poly(L lactic acid-caprolactone), poly(D lactic acid-caprolactone), polyglycine, polyalanine, polyphenylalanine, poly One of glutamic acid, polylysine, polyornithine, polyarginine or its copolymer.
- W-(A) m -L is selected from:
- x is selected from integers between 0-300; in some embodiments, x is selected from integers between 0-50; in some embodiments, x is selected from integers between 0-20; in some embodiments, x is selected from an integer from 3-10; in some embodiments, x is selected from an integer between 0-8;
- x is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,
- y is selected from 1-300; in some embodiments, y is selected from an integer between 5-70; in some embodiments, y is selected from an integer between 5-25; in some embodiments, y is selected from 5-20 an integer between;
- y is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115,
- z is selected from 10-300; in some embodiments, z is selected from an integer between 10-120; in some embodiments, z is selected from an integer between 10-45; in some embodiments, z is selected from 20-25 an integer between;
- z is selected from 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118,
- the temperature-sensitive polymer or compound of the present disclosure is selected from:
- n is selected from an integer between 5-15;
- x is selected from an integer between 3 and 10;
- y is selected from an integer between 5-20;
- n is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15;
- x is selected from 3, 4, 5, 6, 7, 8, 9, 10;
- y is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.
- the temperature-sensitive polymer or compound of the present disclosure is selected from:
- n is selected from an integer between 5-15;
- y is selected from an integer between 5-20;
- n is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15;
- y is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.
- the temperature-sensitive polymer or compound of the present disclosure is selected from:
- n is selected from an integer between 5-15;
- x is selected from an integer between 3 and 10;
- y is selected from an integer between 5-20;
- n is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15;
- x is selected from 3, 4, 5, 6, 7, 8, 9, 10;
- y is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.
- the temperature-sensitive polymer or compound of the present disclosure is selected from:
- n is selected from an integer between 5-15;
- z is selected from an integer between 15-25;
- n is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15;
- z is selected from 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25.
- the temperature-sensitive polymer or compound of the present disclosure is selected from:
- n is selected from an integer between 5-15;
- z is selected from an integer between 15-25;
- n is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15;
- z is selected from 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25.
- the temperature-sensitive polymer or compound of the present disclosure is selected from:
- n is selected from an integer between 5-15;
- x is selected from an integer between 3 and 10;
- y is selected from an integer between 5-20;
- n is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15;
- x is selected from 3, 4, 5, 6, 7, 8, 9, 10;
- y is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.
- the temperature-sensitive polymer or compound of the present disclosure is selected from:
- n is selected from an integer between 5-15;
- x is selected from an integer between 3 and 10;
- y is selected from an integer between 5-20;
- n is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15;
- x is selected from 3, 4, 5, 6, 7, 8, 9, 10;
- y is selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20.
- the present disclosure also provides a method for preparing the temperature-sensitive polymer or compound, which comprises: an AB-type amphiphilic copolymer and an acid anhydride, acid chloride, active ester or carboxylic acid containing an aromatic ring or a heteroaromatic ring in a condensing agent or catalyst Under the action, prepared by chemical coupling.
- the condensing agent is selected from the group consisting of dicyclohexylcarbodiimide, diisopropylcarbodiimide, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. one or more.
- the catalyst is selected from one or more of 4-dimethylaminopyridine, 1-hydroxybenzotriazole, and 4-pyrrolidinopyridine.
- the AB-type amphiphilic copolymer is an amphiphilic copolymer containing a hydrophobic block and a hydrophilic block.
- the hydrophilic block is selected from polyethylene glycol or polyvinylpyrrolidone
- the hydrophobic block is selected from polyester or polyamino acid
- the hydrophobic block is selected from the group consisting of poly-DL-lactic acid, poly-D-lactic acid, poly-L-lactic acid, poly(DL-lactic-glycolic acid), poly(L-lactic-glycolic acid), poly( D-lactic acid-glycolic acid), poly-caprolactone, poly(DL lactic acid-caprolactone), poly(L lactic acid-caprolactone), poly(D lactic acid-caprolactone), polyglycine, polyalanine , one of polyphenylalanine, polyglutamic acid, polylysine, polyornithine, polyarginine or its copolymer.
- the hydrophilic block is selected from polyethylene glycol; in some embodiments, the hydrophilic block is selected from the form of monomethyl ether, monoethyl ether, dimethyl ether, or glycerol ether. polyethylene glycol; in some embodiments, the AB-type amphiphilic copolymer is mPEG-PLA, mPEG-PLGA.
- the present disclosure also provides a composition or pharmaceutical composition comprising the thermosensitive polymer described in the present disclosure or the compound described in the present disclosure.
- the composition or pharmaceutical composition further comprises a vehicle; in some embodiments, the vehicle is selected from the group consisting of phosphate buffered solution, purified water, and physiological saline.
- the concentration of the temperature-sensitive polymer or compound in the composition or pharmaceutical composition is 1-80 wt%; -40wt%, 5-30wt%.
- the temperature-sensitive polymer or compound is present at a concentration of about 1, 2, 3, 4, 5, 6, 7, 8, 9 wt% in the composition or pharmaceutical composition , 10wt%, 11wt%, 12wt%, 13wt%, 14wt%, 15wt%, 16wt%, 17wt%, 18wt%, 19wt%, 20wt%, 21wt%, 22wt%, 23wt%, 24wt%, 25wt%, 26wt% %, 27wt%, 28wt%, 29wt%, 30wt%, 31wt%, 32wt%, 33wt%, 34wt%, 35wt%, 36wt%, 37wt%, 38wt%, 39wt%, 40wt%, 41wt%, 42wt%, 43wt%, 44wt%, 45wt%, 46wt%, 47wt%, 48wt%, 49wt%, 50wt%, 51wt%,
- composition or pharmaceutical composition further comprises a drug or biologically active agent.
- the drug or biologically active agent includes, but is not limited to, nucleic acids, nucleotides, oligonucleotides, aptamers, siRNA, small molecule drugs, sugars, polysaccharides, hormones, polypeptides, proteins, enzymes, cells Factors, antibodies, vaccines and combinations thereof.
- nucleic acids nucleotides, oligonucleotides, aptamers, siRNA, small molecule drugs, sugars, polysaccharides, hormones, polypeptides, proteins, enzymes, cells Factors, antibodies, vaccines and combinations thereof.
- nucleic acids nucleotides
- oligonucleotides aptamers
- siRNA small molecule drugs
- sugars polysaccharides
- hormones polypeptides
- proteins proteins
- enzymes enzymes
- cells Factors antibodies
- vaccines and combinations thereof.
- Herceptin Herceptin, Interleukin-2, etc.
- the drug or biologically active agent is an active ingredient for the treatment of human or animal diseases, which can be selected from antitumor drugs, cardiovascular drugs, anti-infective drugs, antifungal drugs, antiviral drugs, antiallergic drugs, Anti-inflammatory drugs, endocrine drugs, psychotropic drugs, antibiotics, immunosuppressants, vitamins or anesthetics, etc.
- the drug or biologically active agent in the composition is released in a sustained and/or controlled release manner.
- composition or pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or excipient.
- the unit dose of the composition or pharmaceutical composition is 0.001 mg to 1000 mg.
- the composition contains 0.01-99.99% of a pharmaceutical or biologically active agent or a pharmaceutically acceptable salt thereof, based on the total weight of the composition or pharmaceutical composition. In certain embodiments, the composition contains 0.1-99.9% of a drug or biologically active agent or a pharmaceutically acceptable salt thereof. In certain embodiments, the composition contains 0.5%-99.5% of a drug or biologically active agent or a pharmaceutically acceptable salt thereof. In certain embodiments, the composition contains from 1% to 99% of a drug or biologically active agent or a pharmaceutically acceptable salt thereof. In certain embodiments, the composition contains 2% to 98% of a drug or biologically active agent or a pharmaceutically acceptable salt thereof.
- the composition or pharmaceutical composition contains from 0.01% to 99.99% of a pharmaceutically acceptable excipient, based on the total weight of the composition or pharmaceutical composition. In certain embodiments, the composition or pharmaceutical composition contains 0.1%-99.9% of a pharmaceutically acceptable excipient. In certain embodiments, the composition or pharmaceutical composition contains 0.5%-99.5% of a pharmaceutically acceptable excipient. In certain embodiments, the composition or pharmaceutical composition contains 1%-99% of a pharmaceutically acceptable excipient. In certain embodiments, the composition or pharmaceutical composition contains 2%-98% of a pharmaceutically acceptable excipient.
- the composition or pharmaceutical composition undergoes a solution-gel phase transition with increasing temperature, and the temperature of the solution-gel phase transition is 4-40°C; in some embodiments, the solution-gel phase transition The temperature of the phase transition is from about 10 to about 37°C, from about 20 to about 37°C. In some embodiments, the temperature of the solution-gel phase transition is human body temperature.
- the temperature of the solution-gel phase transition of the composition or pharmaceutical composition is about 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C °C, 13°C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C or 40°C.
- the temperature-sensitive polymers or compounds or compositions or pharmaceutical compositions of the present disclosure are injectable.
- the present disclosure also provides a hydrogel comprising the temperature-sensitive polymer described in the present disclosure, or the compound described in the present disclosure, or the composition or pharmaceutical composition described in the present disclosure.
- the hydrogel undergoes a solution-gel phase transition with increasing temperature, and the temperature of the solution-gel phase transition is 4-40°C; in some embodiments, the temperature of the solution-gel phase transition is About 10 to about 37°C, about 20 to about 37°C. In some embodiments, the temperature of the solution-gel phase transition is human body temperature.
- the temperature of the solution-gel phase transition of the hydrogel is about 4°C, 5°C, 6°C, 7°C, 8°C, 9°C, 10°C, 11°C, 12°C, 13°C °C, 14°C, 15°C, 16°C, 17°C, 18°C, 19°C, 20°C, 21°C, 22°C, 23°C, 24°C, 25°C, 26°C, 27°C, 28°C, 29°C, 30°C, 31°C, 32°C, 33°C, 34°C, 35°C, 36°C, 37°C, 38°C, 39°C or 40°C.
- the present disclosure provides a preparation method of a hydrogel comprising the following steps:
- step (2) Dissolving the star-shaped copolymer described in step (1) in a solvent, a hydrogel is spontaneously formed near body temperature (37° C.).
- the condensing agent is selected from the group consisting of dicyclohexylcarbodiimide, diisopropylcarbodiimide, and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide. one or more.
- the catalyst is selected from one or more of 4-dimethylaminopyridine, 1-hydroxybenzotriazole, and 4-pyrrolidinopyridine.
- the present disclosure also provides a method of enhancing the solubility of a drug or biologically active agent comprising mixing the drug or biologically active agent in a thermosensitive polymer or compound or composition or hydrogel of the present disclosure.
- the present disclosure also provides a method of slow or controlled release of a drug or biologically active agent comprising mixing the drug or biologically active agent in the temperature-sensitive polymer or compound or composition or hydrogel of the present disclosure.
- the present disclosure also provides a method of enhancing the stability of a drug or biologically active agent comprising mixing the drug or biologically active agent in a thermosensitive polymer or compound or composition or hydrogel of the present disclosure.
- the present disclosure also provides a method of treating and/or preventing a disease comprising the step of injecting a thermosensitive polymer or compound or composition or hydrogel of the present disclosure into a physiological environment.
- the disease in the present disclosure is selected from, but not limited to, vascular disease, tumor disease, diabetes, immune system disease, and the like.
- the dosage used in the methods of treatment and/or prevention of the present disclosure will generally vary with the severity of the disease, the weight of the patient, and the relative efficacy of the compound.
- a suitable unit dose may range from 0.1 to 1000 mg.
- thermosensitive polymer or compound or composition or pharmaceutical composition or hydrogel of the present disclosure has thermosensitive properties, can be in a solution state at or below room temperature, and transform into a gel state at human body temperature.
- the thermosensitive polymers or compounds or compositions or hydrogels blended with drugs or biologically active agents can be easily and efficiently injected (including but not limited to minimally invasive means such as catheters, needles, etc.) to specific sites (for example, targeted administration).
- the drug is applied to the surgical defect site, near the surgical site or in the adjacent subcutaneous tissue).
- the temperature-sensitive polymer or compound or composition or pharmaceutical composition or hydrogel of the present disclosure forms a gel in situ at body temperature, as a long-acting sustained-release preparation, through the dual action of drug diffusion and gel degradation to achieve drug or Smooth and slow release of biologically active agents.
- the solution of the temperature-sensitive polymer or compound or combination or pharmaceutical composition or hydrogel of the present disclosure reaches the lesion site, its fluidity can make the shape of the formed gel better fit the shape of the defect site, and avoid the material and the defect. Gaps or lumps form between tissues.
- the temperature-sensitive polymer or compound or composition or pharmaceutical composition or hydrogel solution of the present disclosure is thoroughly mixed with drugs, biologically active agents, cells, etc., and after injection into the body, forms a gel, which forms a reservoir in drug delivery.
- thermosensitive polymer or compound or composition or pharmaceutical composition or hydrogel of the present disclosure is a biodegradable or bioabsorbable material, which can be decomposed or degraded into non-toxic components in vivo, which is safe for patients and its surrounding tissues Produces as little irritation as possible and is a compatible medium for the drug.
- the temperature-sensitive polymer or compound or composition or pharmaceutical composition or hydrogel of the present disclosure has a special topology, the degree of entanglement of the chain segments is higher than that of the linear polymer, and the drug embedded in it is more difficult to dissolve.
- thermosensitive polymer or compound or composition or pharmaceutical composition or hydrogel of the present disclosure has a smaller hydrodynamic volume in solution than a single linear polymer, compared to a linear polymer of the same molecular weight
- the viscosity is small, and it is not easy to be blocked in the blood.
- the temperature-sensitive polymer or compound or composition or pharmaceutical composition of the present disclosure is easy to self-assemble into micelles, and it is easier to form a bridged structure between the micelles after the micelles are formed, thereby forming a temperature-sensitive hydrogel, and the hydrogel has better anti-swelling properties.
- the temperature-sensitive polymers or compounds of the present disclosure may exist in particular geometric or stereoisomeric forms.
- This disclosure contemplates all such thermosensitive polymers or compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers , diastereomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, All such mixtures are within the scope of this disclosure. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers, as well as mixtures thereof, are included within the scope of this disclosure unless otherwise indicated.
- the temperature-sensitive polymers or compounds of the present disclosure may be asymmetric, eg, having one or more stereoisomers. Without specifying configuration, all stereoisomers are included, such as enantiomers and diastereomers.
- the asymmetric carbon-containing thermosensitive polymers or compounds of the present disclosure can be isolated in optically pure or racemic forms. Optically pure forms can be resolved from racemic mixtures or synthesized by using chiral starting materials or chiral reagents.
- the bond Indicates an unspecified configuration, i.e. if a chiral isomer exists in the chemical structure, the bond can be or or both and Two configurations.
- the bond may include all isomers, such as rotamers, geometric isomers, Enantiomers, Racemates and Enantiomers.
- the bond no configuration is specified, i.e. the bond The configuration can be E or Z, or both E and Z configurations.
- Optically active (R)- and (S)-isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If an enantiomer of a thermosensitive polymer or compound of the present disclosure is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer.
- a diastereomeric salt is formed with an appropriate optically active acid or base, followed by conventional methods known in the art
- the diastereoisomers were resolved and the pure enantiomers recovered.
- separation of enantiomers and diastereomers is usually accomplished by the use of chromatography employing a chiral stationary phase, optionally in combination with chemical derivatization (eg, from amines to amino groups) formate).
- the present disclosure also includes certain isotopically-labeled compounds of the present disclosure which are identical to those described herein, but wherein one or more atoms are replaced by an atom having an atomic weight or mass number different from that normally found in nature.
- isotopes that can be incorporated into the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, such as 2H, 3H , 11C , 13C , 14C , 13 , respectively N, 15 N, 15 O, 17 O, 18 O, 31 P, 32 P, 35 S, 18 F, 123 I, 125 I and 36 Cl and the like.
- deuterium when a position is specifically designated as deuterium (D), the position is understood to have an abundance of deuterium (ie, at least 1000 times greater than the natural abundance of deuterium (which is 0.015%)) % of deuterium incorporated).
- Exemplary compounds having natural abundance greater than deuterium may be at least 1000 times more abundant deuterium, at least 2000 times more abundant deuterium, at least 3000 times more abundant deuterium, at least 4000 times more abundant deuterium, at least 4000 times more abundant 5000 times more abundant deuterium, at least 6000 times more abundant deuterium or more abundant deuterium.
- the present disclosure also includes compounds in various deuterated forms. Each available hydrogen atom attached to a carbon atom can be independently replaced by a deuterium atom.
- deuterated starting materials can be used in preparing deuterated forms of the compounds, or they can be synthesized using conventional techniques using deuterated reagents including, but not limited to, deuterated borane, trideuterated borane in tetrahydrofuran , Deuterated lithium aluminum hydride, deuterated iodoethane and deuterated iodomethane, etc.
- C 1-6 alkyl optionally substituted by halogen or cyano means that halogen or cyano may but need not be present, and the description includes the case where the alkyl is substituted by halogen or cyano and the case where the alkyl is not substituted by halogen and cyano substitution.
- linear means that the polymer has no or substantially no branching units and thus the polymer backbone has a terminal number of two.
- star means that the polymer backbone has at least one branching position and thus at least 3 ends, eg 3, 4, 5, 6, 7, 8, 9, 10 ends.
- biodegradable refers to the ability of a polymer to chemically degrade or decompose in vivo to produce non-toxic components, at the same or different rate as the drug release rate.
- polymer refers to a molecule containing a plurality of covalently linked monomer units, and can include branched, dendritic, and star polymers, as well as linear polymers.
- the term also includes homopolymers, copolymers and combinations thereof, such as random copolymers, block copolymers and graft copolymers, as well as uncrosslinked polymers and slightly to moderately to substantially crosslinked polymers.
- solution-gel phase transition temperature is also sometimes referred to as the lower critical gel temperature, gelling temperature, used interchangeably, and refers to the transition of a polymer solution from a solution state to a gel as the temperature increases state temperature.
- thermosensitivity refers to the property that when the temperature of the solution is above the temperature of the polymer's solution-gel phase transition, the increase in temperature causes rearrangement and alignment of the polymer chains, resulting in Gelling into a three-dimensional structure, the solution viscosity of the polymer increases spontaneously, and in many cases the copolymer transforms into a semisolid gel. All gel-producing interactions are physical reactions that do not require the formation or breaking of covalent bonds.
- polymer solution means that when applied to the polymer contained in the solution, the solution is maintained at a temperature below the gelation temperature of the polymer. temperature.
- gel and “hydrogel” are used interchangeably and refer to a swollen aqueous network of finely dispersed polymer chains that are insoluble in water, with the polymer molecules in the outer or dispersed outer phase, and the water (or aqueous solution) ) to form an internal or dispersed phase.
- a semisolid phase that spontaneously forms from a polymer solution or hydrogel solution when the temperature is raised to or above the gelation temperature of the polymer.
- polyethylene glycol PEG
- PEO poly(ethylene oxide)
- poly(oxyethylene) PEG
- polylactic acid-co-glycolic acid refers to those obtained by the copolycondensation of lactic acid and glycolic acid or by alpha-hydroxy acid Precursors such as copolymers obtained by ring-opening polymerization of glycolide or lactide.
- lactate refers to those obtained by the copolycondensation of lactic acid and glycolic acid or by alpha-hydroxy acid Precursors such as copolymers obtained by ring-opening polymerization of glycolide or lactide.
- lactate refers to those obtained by the copolycondensation of lactic acid and glycolic acid or by alpha-hydroxy acid Precursors such as copolymers obtained by ring-opening polymerization of glycolide or lactide.
- lactate lactate
- glycolide and glycolide
- PCLA polylactic acid-polycaprolactone copolymer
- PCLA poly( ⁇ -caprolactone-co-lactide)
- biocompatible refers to a substance that is non-toxic within the dosage range, chemically inert, and substantially non-immunogenic and substantially insoluble in blood in a patient.
- a biocompatible material is one that does not cause a significant inflammatory, immune or toxic response when administered to an individual.
- alkyl refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2- Methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3 -Dimethylbutyl, 2-ethylbutyl, 2-methylp
- alkyl groups containing 1 to 6 carbon atoms include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl , n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3 -Methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethyl Butyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl , 2,3-dimethylbutyl, etc.
- Alkyl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, preferably one or more of the following groups, independently selected from alkanes group, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkane oxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxyl or carboxylate.
- alkoxy refers to -O-(alkyl) and -O-(unsubstituted cycloalkyl), wherein alkyl is as defined above.
- alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy.
- Alkoxy can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from halogen, deuterium, hydroxyl, oxo, nitro, cyano , C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 3-6 cycloalkoxy, 3- to 6-membered heterocycloalkoxy , C 3-8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl, the C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2-6 Alkynoxy, C 3-6 cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl are optionally selected by one or more Substituted from halogen, deuterium, hydroxyl,
- alkenyl refers to a straight or branched chain non-aromatic hydrocarbon group containing at least one carbon-carbon double bond and having from 2 to 10 carbon atoms. Up to 5 carbon-carbon double bonds may be present in such groups.
- C2 - C6 alkenyl is defined as an alkenyl group having 2-6 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl, propenyl, butenyl, and cyclohexenyl.
- the straight, branched or cyclic portion of the alkenyl group can contain double bonds and is optionally mono-, di-, tri-, tetra- or penta-substituted at any position allowed by normal valences.
- alkynyl refers to a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Up to 5 carbon-carbon triple bonds can be present.
- C2 - C6alkynyl means an alkenyl group having 2-6 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl, 2-propynyl, and 2-butynyl.
- the straight-chain, branched portion of the alkynyl group can contain triple bonds as normal valences allow, and is optionally mono-, di-, tri-, tetra- or penta-substituted at any position permitted by normal valences.
- cycloalkyl or “carbocycle” refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing 3 to 20 carbon atoms, preferably 3 to 7 carbon atoms.
- monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, and the like; polycyclic cycloalkyl groups include spiro Ring, fused and bridged cycloalkyl groups.
- Cycloalkyl groups may be substituted or unsubstituted, and when substituted, the substituents may be substituted at any available point of attachment, preferably one or more of the following groups, independently selected from halogen, deuterium, hydroxy, Oxo, nitro, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 3-6 cycloalkoxy, 3 to 6-membered heterocycloalkoxy, C 3-8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl, the C 1-6 alkyl, C 1-6 alkoxy, C 2-6 Alkenyloxy, C 2-6 alkynyloxy, C 3-6 cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl
- the substituents may be substituted at any available point of attachment,
- the cycloalkyl ring may be fused to an aryl or heteroaryl ring, wherein the ring attached to the parent structure is a cycloalkyl, non-limiting examples include indanyl, tetrahydronaphthyl, benzo rings Heptyl, etc.
- heterocycloalkyl or “heterocycle” or “heterocyclyl” refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 ring atoms, of which one or more rings Atoms are heteroatoms selected from nitrogen, oxygen or S(O) m (where m is an integer from 0 to 2), but excluding ring moieties of -OO-, -OS- or -SS-, the remaining ring atoms are carbon.
- it contains 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably 3 to 7 ring atoms.
- Non-limiting examples of monocyclic heterocycloalkyl include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piper pyridyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc.
- Polycyclic heterocycloalkyl groups include spiro, fused and bridged ring heterocycloalkyl groups.
- Non-limiting examples of "heterocycloalkyl" include:
- heterocycloalkyl ring may be fused to an aryl or heteroaryl ring, wherein the ring attached to the parent structure is a heterocycloalkyl, non-limiting examples of which include:
- Heterocycloalkyl can be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from halogen, deuterium, hydroxy, oxo, nitro, cyano base, C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 3-6 cycloalkoxy, 3- to 6-membered heterocycloalkoxy base, C 3-8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl, the C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2- 6 -alkynyloxy, C 3-6 cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl optionally replaced by one or more Substituted from halogen, deuter
- aryl refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (ie, rings that share adjacent pairs of carbon atoms) groups having a conjugated pi-electron system, preferably 6 to 12 membered, such as benzene base and naphthyl.
- the aryl ring can be fused to a heteroaryl, heterocycloalkyl or cycloalkyl ring, wherein the ring linked to the parent structure is an aryl ring, non-limiting examples of which include:
- Aryl may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from halogen, deuterium, hydroxyl, oxo, nitro, cyano, C1 -6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 3-6 cycloalkoxy, 3 to 6 membered heterocycloalkoxy, C 3 -8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl, the C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy , C 3-6 cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl optionally by one or more selected from halogen, Deuterium, hydroxyl, oxo, nitro
- heteroaryl refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen.
- the heteroaryl group is preferably 6- to 12-membered, more preferably 5- or 6-membered.
- Non-limiting examples thereof include: imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl , thiadiazole, pyrazinyl, triazolyl, indazolyl, benzimidazolyl, Wait.
- the heteroaryl ring can be fused to an aryl, heterocycloalkyl or cycloalkyl ring, wherein the ring linked to the parent structure is a heteroaryl ring, non-limiting examples of which include:
- Heteroaryl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from halogen, deuterium, hydroxy, oxo, nitro, cyano , C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2-6 alkynyloxy, C 3-6 cycloalkoxy, 3- to 6-membered heterocycloalkoxy , C 3-8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl, the C 1-6 alkyl, C 1-6 alkoxy, C 2-6 alkenyloxy, C 2-6 Alkynoxy, C 3-6 cycloalkoxy, 3- to 6-membered heterocycloalkoxy, C 3-8 cycloalkenyloxy, 5- to 6-membered aryl or heteroaryl are optionally selected by one or more Substituted from halogen, deuterium, hydroxyl
- sub- in the name of a chemical moiety refers to any divalent, carbon-containing species including, but not limited to, alkylene, alkenylene, alkynylene, cycloalkylene, heterocycloalkylene, Aryl, heteroarylene, cyclylene, and heterocyclylene.
- the two linkages on the divalent moiety can occur on the same atom or on different atoms.
- Alkylene refers to the remainder of the alkane molecule after the removal of 2 hydrogen atoms, including straight and branched chain subgroups of 1 to 20 carbon atoms.
- An alkylene group containing 1 to 6 carbon atoms non-limiting examples include methylene ( -CH2- ), ethylene (eg -CH2CH2- or -CH( CH3 ) -), propylene base (eg -CH 2 CH 2 CH 2 - or -CH(CH 2 CH 3 )-), butylene (eg - CH 2 CH 2 CH 2 CH 2 -).
- Alkylene may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, preferably one or more of the following groups, independently selected from halogen, deuterium, hydroxy, nitro, cyano or amino.
- alkenylene refers to an alkene having two monovalent radical centers derived by removal of two hydrogen atoms from the same or two different carbon atoms of the parent alkene.
- Alkenylene groups can be substituted or unsubstituted.
- the substituents are preferably independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylsulfo, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl , one or more of heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, preferably one to five, more preferably One to three substituents.
- alkynylene refers to an alkynyl group having two monovalent radical centers derived by removal of two hydrogen atoms from the same or two different carbon atoms of the parent alkyne.
- Typical alkynylene groups include, but are not limited to, ethynyl (-C ⁇ C-), propargylene ( -CH2C ⁇ C- ), and 1 - pentynylene ( -CH2CH2CH2C ⁇ C-).
- arylene refers to an aryl group having two monovalent radical centers derived by removal of two hydrogen atoms from the same or two different carbon atoms of a parent aryl group.
- heteroarylene refers to a heteroaryl group, as defined above, having two hydrogen atoms removed from the same or two different carbon atoms of the parent heteroaryl group or hydrogen removed from one carbon atom and one Two monovalent radical centers derived from hydrogen are removed from the nitrogen atom.
- heteroalkylene refers to an alkylene group, as defined herein, wherein one or more carbon atoms are replaced with oxygen, sulfur, or nitrogen atoms.
- cycloalkylene refers to a group formed by the formal elimination of two hydrogen atoms from a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon containing 3 to 20 carbon atoms, preferably 3 to 12 carbon atoms
- Non-limiting examples of monocyclic cycloalkylenes include cyclopropylene, cyclobutylene, cyclopentylene, cyclohexylene, cycloheptylene, cyclooctylene, 1,2-cyclopropylene , 1,3-cyclobutylene, 1,4-cyclohexylene, etc.
- Polycyclic cycloalkylenes include spiro, fused, and bridged cycloalkylenes.
- heterocycloalkylene refers to a divalent group formed from a heterocyclyl group and two substituents on a single ring carbon.
- hydroxy refers to the -OH group.
- halogen refers to fluorine, chlorine, bromine or iodine.
- haloalkyl refers to an alkyl group substituted with halogen, wherein alkyl is as defined above.
- haloalkoxy refers to an alkoxy group, as defined in this disclosure, optionally substituted with one or more halogen atoms.
- cyano refers to -CN.
- nitro refers to -NO2 .
- amino refers to -NH2 .
- substituted means that any one or more hydrogen atoms on the designated atom (usually carbon, oxygen, and nitrogen atoms) are replaced by any group as defined herein, provided that the designated atom's normal valence is not exceeded and Substitution produces stable compounds.
- Non-limiting examples of substituents include C1 - C6 alkyl, C2 - C6 alkenyl, C2 - C6 alkynyl, cyano, hydroxy, oxo, carboxyl, cycloalkyl, cycloalkenyl , heterocyclyl, heteroaryl, aryl, ketone, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, or halogen (eg, F, Cl, Br, I).
- Substituted with one or more means that it may be substituted with single or multiple substituents. When substituted by a plurality of substituents, it may be a plurality of the same substituents, or a combination of one or a plurality of different substituents.
- beneficial or desired dose refers to the amount of drug, compound or pharmaceutical composition necessary to obtain any one or more beneficial or desired therapeutic results.
- beneficial or desired results include elimination or reduction of risk, reduction in severity, or delay in onset of disorders, including biochemical, tissue academic and/or behavioral symptoms.
- beneficial or desired outcomes include clinical outcomes, such as reducing the incidence or amelioration of one or more symptoms of a disorder associated with various target genes, target mRNAs, or target proteins, reducing the need to treat the disorder
- the dose of the other agent enhances the therapeutic effect of the other agent, and/or delays the progression of the target gene, target mRNA or target protein-related disorder in the patient.
- pharmaceutical composition means a mixture comprising one or more compounds described herein, or a physiologically acceptable salt or prodrug thereof, with other chemical components, and other components such as a physiologically acceptable carrier and excipient.
- the purpose of the pharmaceutical composition is to facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
- pharmaceutically acceptable excipient or “pharmaceutically acceptable excipient” includes, but is not limited to, any adjuvant, carrier, excipient that has been approved by the U.S. Food and Drug Administration and is acceptable for use in humans or livestock animals. Excipients, glidants, sweeteners, diluents, preservatives, dyes/colorants, flavoring agents, surfactants, wetting agents, dispersing agents, suspending agents, stabilizers, isotonic agents, solvents or emulsifier.
- FIG. 1 is the 1 H-NMR spectrum of the diblock polymer mPEG-PLGA.
- FIG. 2 is the 1 H-NMR spectrum of the star-shaped multi-armed polymer PMDA-mPEG-PLGA.
- Figure 3 is the phase diagram of the solution-gel transition of the star-shaped multi-armed polymer PMDA-mPEG-PLGA, in which the triangles represent: the temperature at which the polymer gel precipitates at a certain concentration; the diamonds represent: at a certain concentration, the polymerization The temperature at which the solution turns into a gel.
- FIG. 4 is the 1 H-NMR spectrum of the diblock polymer mPEG-PLA.
- FIG. 5 is the 1 H-NMR spectrum of the star-shaped multi-arm polymer PMDA-mPEG-PLA.
- Fig. 6 is the phase diagram of the solution-gel transition of the star-shaped multi-armed polymer PMDA-mPEG-PLA, in which the squares indicate the temperature at which the polymer gel precipitates at a certain concentration; the diamonds indicate: under a certain concentration, the polymerization The temperature at which the solution turns into a gel.
- Figure 7 is the release curve of PMDA-mPEG-PLA flurbiprofen hydrogel.
- FIG. 8 is a 1 H-NMR spectrum of CMPEG.
- Figure 9 is a 1 H-NMR spectrum of the non-aromatic core star polymer 4-arm PLGA.
- Figure 10 is the 1 H-NMR spectrum of the non-aromatic core star polymer 4-arm PLGA-PEG.
- Figure 11 is the phase diagram of the non-aromatic core star polymer 4-arm PLGA-PEG solution-gel transition, in which the square represents the temperature at which the polymer gel precipitates at a certain concentration; the diamond represents: at a certain concentration temperature at which the polymer solution becomes a gel.
- Figure 12 is the release profile of the non-aromatic core star polymer 4-arm PLGA-PEG flurbiprofen hydrogel.
- NMR nuclear magnetic resonance
- HPLC High performance liquid chromatography
- the known starting materials in the present disclosure can be synthesized by using or according to methods known in the art, or can be purchased from Aldrich Chemical Company, Adamas Reagent, Jinan Daigang Bioengineering and other companies.
- reaction can be carried out in an argon atmosphere or a nitrogen atmosphere.
- Argon or nitrogen atmosphere means that the reaction flask is connected to an argon or nitrogen balloon with a volume of about 1 L.
- the solution refers to an aqueous solution.
- reaction temperature is room temperature, which is 20°C to 30°C.
- the properties of the block polymer were measured, and the number-average and weight-average molecular weights (Mn, Mw) of the above-mentioned polymers were measured by gel permeation chromatography (GPC, polyethylene glycol as the standard sample) to be 1557 and 2109, respectively.
- the molecular weight distribution coefficient (Mw/Mn) was 1.35.
- the copolymer is soluble in water and undergoes a reversible solution-gel transition with increasing temperature.
- the structure of the diblock polymer mPEG-PLGA is:
- n 12
- x 3
- y 13
- the properties of the block polymer were measured, and the number-average and weight-average molecular weights (Mn, Mw) of the above-mentioned polymers were measured by gel permeation chromatography (GPC, polyethylene glycol as the standard sample) to be 1557 and 2109, respectively.
- the molecular weight distribution coefficient (Mw/Mn) was 1.35.
- the copolymer is soluble in water and undergoes a reversible solution-gel transition with increasing temperature.
- Figure 1 is the 1 H-NMR spectrum of the polymer mPEG-PLGA, the hydrogen at 3.65 ppm comes from the methylene group in mPEG, the hydrogen at 3.38 ppm comes from the methyl group in mPEG, and the hydrogen at 4.8 ppm comes from The methylene group in glycolide and the hydrogen at 5.1 ppm come from the methine group in D,L-lactide. Calculated by the integral area, the result is consistent with the charging ratio.
- the number-average and weight-average molecular weights (Mn, Mw) of the above polymers measured by gel permeation chromatography (GPC, polyethylene glycol as the standard sample) were 5112 and 5836, respectively, and the molecular weight distribution coefficient (Mw/Mn) was 1.14 .
- the structure of star-shaped multi-arm polymer PMDA-mPEG-PLGA is:
- n 12
- x 3
- y 16
- Figure 2 is the 1 H-NMR spectrum of the star-shaped multi-armed polymer PMDA-mPEG-PLGA. Except for the hydrogen containing the above-mentioned two-block polymer, a new peak appears at 8.2 ppm, which is the benzene in PMDA. The hydrogen on the ring proves the successful synthesis of star polymer PMDA-mPEG-PLGA.
- Figure 3 is a phase diagram of the star-shaped multi-armed polymer PMDA-mPEG-PLGA solution-gel transition.
- the sample bottle is immersed in a water bath at 24-80°C, and is immediately inverted to 180° after equilibrating for 15 minutes. If the sample does not flow significantly within 30s, the sample is considered to be in a gel state, and the temperature at this time is the solution-gel transition temperature. .
- the triangles represent the temperature at which the polymer gel precipitates at a certain concentration; the diamonds represent the temperature at which the polymer solution becomes a gel at a certain concentration.
- the properties of the block polymer were determined, and the number-average and weight-average molecular weights (Mn, Mw) of the above-mentioned polymers were measured by gel permeation chromatography (GPC, polyethylene glycol as the standard sample) to be 1172 and 1355, respectively.
- the distribution coefficient (Mw/Mn) was 1.16.
- the structure of the diblock polymer mPEG-PLA is:
- n 12 and y is 9.
- Figure 4 is the 1 H-NMR spectrum of the polymer mPEG-PLA, the hydrogen at 3.65 ppm comes from the methylene group in mPEG, the hydrogen at 3.38 ppm comes from the methyl group in mPEG, and the hydrogen at 5.1 ppm comes from The methine group in D, L-lactide is calculated by the integral area, and the result is consistent with the feeding ratio.
- the structure of star-shaped multi-arm polymer PMDA-mPEG-PLA is:
- n 12 and y is 10.
- Figure 5 is the 1 H-NMR spectrum of the star-shaped multi-armed polymer PMDA-mPEG-PLA.
- a new peak appears at 8.2 ppm, which is the benzene in PMDA.
- the hydrogen on the ring proves the successful synthesis of star polymer PMDA-mPEG-PLA.
- Figure 6 is a phase diagram of the star-shaped multi-armed polymer PMDA-mPEG-PLA solution-gel transition.
- the sample bottle is immersed in a water bath at 24-80°C, and is immediately inverted to 180° after equilibrating for 15 minutes. If the sample does not flow significantly within 30s, the sample is considered to be in a gel state, and the temperature at this time is the solution-gel transition temperature. .
- the square represents the temperature at which the polymer gel precipitates at a certain concentration; the diamond represents the temperature at which the polymer solution becomes a gel at a certain concentration.
- Figure 7 shows the release curve of PMDA-mPEG-PLA flurbiprofen hydrogel. With the prolongation of release time, the release rate gradually increased, and the final release rate was 96.6%.
- Figure 8 is the 1 H-NMR spectrum of CMPEG, and n-1 is: 11.
- the hydrogen at 3.62 ppm comes from the methylene group in mPEG, and the hydrogen at 3.36 ppm comes from the methyl group in mPEG. base, the hydrogen at 2.62 ppm comes from the methylene group in succinic anhydride.
- the number-average and weight-average molecular weights (Mn, Mw) of the above polymers measured by gel permeation chromatography (GPC, polyethylene glycol as the standard sample) were 3119 and 3706, respectively, and the molecular weight distribution coefficient (Mw/Mn) was 1.19.
- the non-aromatic core star polymer 4-arm PLGA structure is:
- Figure 9 is the 1 H-NMR spectrum of the non-aromatic core polymer 4-arm PLGA, the hydrogen at 1.5 ppm comes from the methyl group in D,L-lactide, and the hydrogen at 4.8 ppm comes from the glycolide methylene, the hydrogen at 4.16ppm comes from the methylene on pentaerythritol and the methine and methylene connected to -OH, the hydrogen at 5.1ppm comes from the methine in D,L-lactide base.
- the number-average and weight-average molecular weights (Mn, Mw) of the above-mentioned polymers measured by gel permeation chromatography (GPC, polyethylene glycol as the standard sample) were 5502 and 7319, respectively, and the molecular weight distribution coefficient (Mw/Mn) was 1.33.
- the structure of 4-arm PLGA-PEG is:
- Figure 10 is the 1 H-NMR spectrum of the non-aromatic core star polymer 4-arm PLGA-PEG, all hydrogens of CMPEG and 4-arm PLGA-PEG can be assigned.
- n-1 is 11
- x is 5
- y is 15.
- Figure 11 is a phase diagram of the non-aromatic core star polymer 4-arm PLGA-PEG solution-gel transition.
- Weigh an appropriate amount of star-shaped polymer use water as a solvent to prepare a solution with a polymer mass content of 10wt% to 35wt%, and carry out the test by the inverted pipe method. Specifically, immerse the sample bottle containing the star-shaped polymer solution in In a 25-74°C water bath, invert 180° immediately after equilibrating for 15 minutes. If the sample does not flow significantly within 30s, the sample is considered to be in a gel state, and the temperature at this time is the solution-gel transition temperature.
- the square represents the temperature at which the polymer gel precipitates at a certain concentration; the diamond represents the temperature at which the polymer solution becomes a gel at a certain concentration.
- the critical gel concentration of PMDA-mPEG-PLGA is 10 wt%, while that of 4-arm PLGA-PEG is 20 wt%.
- Figure 12 shows the release curve of the non-aromatic core star polymer 4-arm PLGA-PEG flurbiprofen hydrogel. With the prolongation of the release time, the release rate gradually increased, but the final release rate was only 26%.
- the PMDA-mPEG-PLA hydrogel showed a higher drug release rate than the 4-arm PLGA-PEG hydrogel, and the PMDA-mPEG-PLA hydrogel was easier to encapsulate the drug.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Polyesters Or Polycarbonates (AREA)
Abstract
Description
Claims (24)
- 一种温敏聚合物,其具有式(I-2)的结构,其中,R 1相同或不同,且各自独立地选自C 1-C 12烷基,所述C 1-C 12烷基任选被选自卤素、羟基、烷氧基、卤代烷氧基、氰基、氨基和硝基的一个或多个取代基取代;环E选自芳基或杂芳基;优选地,环E选自C 6-C 12芳基或5-10元杂芳基;更优选地,环E选自苯基、吡啶基、吡嗪基、吡唑基、三唑基、异噁唑基、噁唑基、噻唑基、噻二唑基、咪唑基、吲唑基或苯并咪唑基;L相同或不同,且各自独立地选自键、-C(O)-、-O-、-S-、-SO-、-SO 2-、-C(O)O-、-NR'-、-C(O)NR'-、亚烷基、亚烯基、亚炔基、亚杂烷基、亚环烷基、亚杂环烷基、亚芳基、亚杂芳基、PEG,所述亚烷基、亚烯基、亚炔基、亚杂烷基、亚环烷基、亚杂环烷基、亚芳基、亚杂芳基任选被选自羟基、烷基、烷氧基、卤代烷基、卤代烷氧基、卤素、羟基、氰基、氨基和硝基的一个或多个取代基取代;A相同或不同,且各自独立地选自疏水性嵌段;B相同或不同,且各自独立地选自亲水性嵌段;W相同或不同,且各自独立地选自键、-O-、-S-、-SO-、-SO 2-、-C(O)-、-C(O)O-、-NR'-、-C(O)NR'-、亚烷基、所述亚烷基任选被选自羟基、烷基、烷氧基、卤代烷基、卤代烷氧基、卤素、羟基、氰基、氨基和硝基的一个或多个取代基取代;R'选自氢、氘、羟基、烷基、烷氧基、环烷基、杂环基、芳基或杂芳基,所述烷基、烷氧基、环烷基、杂环基、芳基或杂芳基任选被选自卤素、羟基、氧代、硝基、氰基的一个或多个取代基取代;m选自1-300之间的整数,优选自5-150之间的整数,进一步优选自10-120之间的整数,更优选自10-45之间的整数,还更优选自15-25之间的整数;n选自1-500之间的整数,优选自5-300之间的整数,进一步优选自10-45之间的整数,更优选自10-30之间的整数,还更优选自10-20之间的整数;a选自1-20之间的整数;优选自2-15之间的整数;进一步优选自3-11之间的整数;还更优选自4-8之间的整数。
- 根据权利要求1所述的温敏聚合物,其中所述亲水性嵌段选自聚乙二醇或聚乙烯吡咯烷酮,所述疏水性嵌段选自聚酯或聚氨基酸;优选地,所述疏水性嵌段选自聚DL-乳酸、聚D-乳酸、聚L-乳酸、聚(DL-乳酸-乙醇酸)、聚(L-乳酸-乙醇酸)、聚(D-乳酸-乙醇酸)、聚-己内酯、聚(DL乳酸-己 内酯)、聚(L乳酸-己内酯)、聚(D乳酸-己内酯)、聚甘氨酸、聚丙氨酸、聚苯丙氨酸、聚谷氨酸、聚赖氨酸、聚鸟氨酸、聚精氨酸中的一种或其共聚物。
- 根据权利要求1或2所述的温敏聚合物,其中所述环E选自苯基。
- 根据权利要求1至4中任一项所述的温敏聚合物,其中L相同或不同,且各自独立地选自键、-C(O)-、-O-、-S-、-SO-、-SO 2-、-C(O)O-、-NR'-、-C(O)NR'-、C 1-C 6亚烷基;R'选自氢、氘、羟基、C 1-C 6烷基、C 1-C 6烷氧基;优选地,L选自-C(O)-、-O-、-C(O)NH-、-C(O)O-,更优选-C(O)-。
- 根据权利要求1至5中任一项所述的温敏聚合物,其中W相同或不同,且各自独立地选自键、-O-、-C(O)-、-NH-,优选-O-。
- 根据权利要求1至6中任一项所述的温敏聚合物,其中,-(B) n-R 1相同或不同,且各自独立地选自-(CH 2CH 2O)n-R 1,其中,R 1相同或不同,且各自独立地选自甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基,优选甲基;n如权利要求1或2所定义。
- 根据权利要求9所述的温敏聚合物,其中,n选自5-15之间的整数;x选自3-10之间的整数;y选自5-20之间的整数;z选自15-25之间的整数。
- 一种化合物,所述化合物结构如权利要求1-10任一项的式(I-2)所示。
- 根据权利要求1至10中任一项所述的温敏聚合物,其分子量分布系数(Mw/Mn)小于2;优选地,分子量分布系数小于1.5。
- 一种制备根据权利要求1-10、12中任一项所述的温敏聚合物的方法,其包括将含有疏水性嵌段和亲水性嵌段的两亲性共聚物与含有芳环或杂芳环的酸酐、酰氯、活性酯或羧酸在缩合剂或催化剂作用下进行化学偶联反应的步骤;优选地,所述缩合剂选自二环己基碳二亚胺、二异丙基碳二亚胺、1-(3-二甲氨基丙基)-3-乙基碳二亚胺中的一种或多种,所述催化剂选自4-二甲氨基吡啶、1-羟基苯并三氮唑、4-吡咯烷基吡啶中的一种或多种。
- 一种组合物,其包含根据权利要求1-10、12中任一项所述的温敏聚合物;优选地,还包含溶媒;更优选地,所述溶媒选自磷酸盐缓冲溶液、纯水或生理盐水。
- 根据权利要求14所述的组合物,其中所述温敏聚合物的浓度为1-80wt%,优选5-50wt%。
- 根据权利要求14或15所述的组合物,其还包含药物或生物活性试剂。
- 根据权利要求16所述的组合物,其中所述药物或生物活性试剂以缓释和/或控释方式释放。
- 根据权利要求14至17中任一项所述的组合物,其是可注射组合物。
- 一种水凝胶,其包含一种或多种根据权利要求1-10、12中任一项所述的温敏聚合物,或根据权利要求14至18中任一项所述的组合物。
- 根据权利要求1-10、12中任一项所述的温敏聚合物或根据权利要求14至18中任一项所述的组合物或根据权利要求19所述的水凝胶,其随温度升高发生溶液-凝胶相转变,所述溶液-凝胶相转变的温度为4-40℃,优选10-37℃,更优选20-37℃。
- 一种增强药物或生物活性试剂的溶解性的方法,其包括将药物或生物活性试剂混合在一种或多种根据权利要求1-10、12中任一项所述的温敏聚合物,或根据权利要求14至18中任一项所述的组合物,或根据权利要求19所述的水凝胶中。
- 一种增强药物或生物活性试剂的稳定性的方法,其包括将药物或生物活性试剂混合在一种或多种根据权利要求1-10、12中任一项所述的温敏聚合物,或根据权利要求14至18中任一项所述的组合物,或根据权利要求19所述的水凝胶中。
- 一种缓释或控释药物或生物活性试剂的方法,其包括将药物或生物活性试剂混合在一种或多种根据权利要求1-10、12中任一项所述的温敏聚合物,或根据权利要求14至18中任一项所述的组合物,或根据权利要求19所述的水凝胶中。
- 一种治疗疾病的方法,其包括将一种或多种权利要求1-10、12任一项所述的温敏聚合物,或权利要求11或12所述的化合物,或权利要求14-18任一项所述的组合物,或权利要求19所述的水凝胶注射入生理环境中的步骤。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023560184A JP2024515495A (ja) | 2021-04-30 | 2022-04-29 | ポリマー及びその組成物 |
CN202280017980.9A CN116963719A (zh) | 2021-04-30 | 2022-04-29 | 一种聚合物及其组合物 |
KR1020237040452A KR20240004604A (ko) | 2021-04-30 | 2022-04-29 | 중합체 및 이의 조성물 |
EP22795024.3A EP4331568A1 (en) | 2021-04-30 | 2022-04-29 | Polymer and composition thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110479406.2 | 2021-04-30 | ||
CN202110479406 | 2021-04-30 | ||
CN202111188454 | 2021-10-12 | ||
CN202111188454.2 | 2021-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022228555A1 true WO2022228555A1 (zh) | 2022-11-03 |
Family
ID=83847789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/090327 WO2022228555A1 (zh) | 2021-04-30 | 2022-04-29 | 一种聚合物及其组合物 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP4331568A1 (zh) |
JP (1) | JP2024515495A (zh) |
KR (1) | KR20240004604A (zh) |
CN (1) | CN116963719A (zh) |
TW (1) | TW202307044A (zh) |
WO (1) | WO2022228555A1 (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1988108A1 (en) * | 2007-05-03 | 2008-11-05 | Sungkyunkwan University Foundation for Corporate Collaboration | Temperature and pH-sensitive block copolymer having having excellent gel strength, method of preparing the same, and drug delivery system using the same |
CN101845120A (zh) * | 2010-03-25 | 2010-09-29 | 淮阴师范学院 | 一种温敏和生物可降解性原位凝胶的合成方法 |
CN107929231A (zh) * | 2017-09-20 | 2018-04-20 | 中国药科大学 | 一种化疗免疫联合治疗的原位温敏凝胶药物递送系统 |
-
2022
- 2022-04-29 KR KR1020237040452A patent/KR20240004604A/ko unknown
- 2022-04-29 CN CN202280017980.9A patent/CN116963719A/zh active Pending
- 2022-04-29 TW TW111116454A patent/TW202307044A/zh unknown
- 2022-04-29 WO PCT/CN2022/090327 patent/WO2022228555A1/zh active Application Filing
- 2022-04-29 JP JP2023560184A patent/JP2024515495A/ja active Pending
- 2022-04-29 EP EP22795024.3A patent/EP4331568A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1988108A1 (en) * | 2007-05-03 | 2008-11-05 | Sungkyunkwan University Foundation for Corporate Collaboration | Temperature and pH-sensitive block copolymer having having excellent gel strength, method of preparing the same, and drug delivery system using the same |
CN101845120A (zh) * | 2010-03-25 | 2010-09-29 | 淮阴师范学院 | 一种温敏和生物可降解性原位凝胶的合成方法 |
CN107929231A (zh) * | 2017-09-20 | 2018-04-20 | 中国药科大学 | 一种化疗免疫联合治疗的原位温敏凝胶药物递送系统 |
Non-Patent Citations (3)
Title |
---|
"Biodegradable block copolymers as injectable drug-delivery systems", NATURE, vol. 388, no. 6645, 28 August 1997 (1997-08-28), pages 860 - 2 |
DHAWAL D. ANKOLA, M. N. V. RAVI KUMAR, FEDERICA CHIELLINI, ROBERTO SOLARO: "Multiblock Copolymers of Lactic Acid and Ethylene Glycol Containing Periodic Side-Chain Carboxyl Groups: Synthesis, Characterization, and Nanoparticle Preparation", MACROMOLECULES, vol. 42, no. 19, 13 October 2009 (2009-10-13), pages 7388 - 7395, XP055064741, ISSN: 0024-9297, DOI: 10.1021/ma9012253 * |
GANUGULA RAGHU, ARORA MEENAKSHI, SAINI PRABHJOT, GUADA MELISSA, KUMAR MAJETI N. V. RAVI: "Next Generation Precision-Polyesters Enabling Optimization of Ligand–Receptor Stoichiometry for Modular Drug Delivery", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 139, no. 21, 31 May 2017 (2017-05-31), pages 7203 - 7216, XP055981257, ISSN: 0002-7863, DOI: 10.1021/jacs.6b13231 * |
Also Published As
Publication number | Publication date |
---|---|
JP2024515495A (ja) | 2024-04-10 |
EP4331568A1 (en) | 2024-03-06 |
TW202307044A (zh) | 2023-02-16 |
KR20240004604A (ko) | 2024-01-11 |
CN116963719A (zh) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6559198B2 (ja) | ポリラクチド組成物およびその使用 | |
TW592726B (en) | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water | |
JP6195587B2 (ja) | 低バーストポリ−(ラクチド/グリコシド)およびポリマーを生成するための方法 | |
JP5121790B2 (ja) | 薬剤送達のための生物分解性ブロックコポリマー組成物 | |
JP6134269B2 (ja) | 生分解性薬物送達組成物 | |
Zhang et al. | Development of biodegradable polymeric paste formulations for taxol: an in vitro and in vivo study | |
AU2012237262A1 (en) | Biodegradable compositions suitable for controlled release | |
CN107952079B (zh) | 一种联合给药的热致凝胶缓释注射剂及其制备方法 | |
KR20190067653A (ko) | 피부용 필러 조성물 | |
Yang et al. | Hydrogels with prolonged release of therapeutic antibody: Block junction chemistry modification of ‘ABA’copolymers provides superior anticancer efficacy | |
US20160058698A1 (en) | Composition for controlled delivery of bioactive agents | |
KR20070122522A (ko) | Peg-폴리(오르토 에스테르) 그라프트 공중합체 및 약학조성물 | |
JP6147664B2 (ja) | 2−ヒドロキシアルキル酸から調製されたポリマーを含む組成物 | |
WO2020100142A1 (en) | Lactide containing polyester-polyethylene glycol triblock thermoresponsive copolymers | |
US20110070320A1 (en) | Biodegradable thermoresponsive 3-arm polyethylene glycol poly(lactide-co-glycolide) copolymer for ginseng administration | |
WO2022228555A1 (zh) | 一种聚合物及其组合物 | |
Jiang et al. | Biodegradable and thermoreversible hydrogels of poly (ethylene glycol)‐poly (ε‐caprolactone‐co‐glycolide)‐poly (ethylene glycol) aqueous solutions | |
CN1916050B (zh) | 可注射温敏性聚(丙交酯-乙交酯-对二氧六环酮)-聚乙二醇嵌段共聚物水凝胶 | |
CN105362223B (zh) | 一种可靶向药物的三嵌段共聚物胶束的制备方法 | |
JP2002537418A (ja) | 生分解可能で注射可能なオリゴマー−ポリマー組成物 | |
Guidotti et al. | Micro/nanoparticles fabricated with triblock PLLA-based copolymers containing PEG-like subunit for controlled drug release: Effect of chemical structure and molecular architecture on drug release profile | |
CA2970617A1 (en) | Alternating and semi-alternating poly(ester-anhydride) copolymers | |
Wang et al. | In situ photo‐crosslinked hydrogels prepared from acrylated 4‐arm‐poly (ethylene glycol)‐poly (ε‐caprolactone) block copolymers for local cancer therapy | |
Wang et al. | Synthesis, Characterization, and Micellization Behavior of Poly (L-lactide) and Poly (ethylene glycol) Block Copolymers in the presence of a Novel Organocatalyst. | |
Khang et al. | Development of biodegradable methoxy poly (ethyleneglycol)-polyesters diblock copolymers as drug carrier for implantable disc |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22795024 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280017980.9 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023560184 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18288970 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20237040452 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022795024 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022795024 Country of ref document: EP Effective date: 20231130 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |